Pharmaceutical Composite Films: Multi-Layer Blister & IV Bag Packaging (2026–2032)
公開 2026/04/09 17:10
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Pharmaceutical Composite Films and Bags - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pharmaceutical Composite Films and Bags market, including market size, share, demand, industry development status, and forecasts for the next few years.
Pharmaceutical manufacturers face a critical challenge: protecting moisture-sensitive and oxygen-sensitive drugs (oral solids, injectables, biologics) from environmental degradation. Single-layer plastic films allow moisture and oxygen transmission, leading to drug instability and reduced shelf life. Pharmaceutical Composite Films and Bags solve this by providing high-performance packaging made by laminating multiple layers with different properties, offering excellent barrier performance, moisture resistance, puncture resistance, and chemical stability, effectively protecting medicines from light, oxygen, and moisture to ensure efficacy and safety. From aluminum-plastic blister films for tablets to multi-layer IV bags for parenteral nutrition, composite films are essential for pharmaceutical packaging. In 2024, the average global price of pharmaceutical composite films and bags is approximately USD 2,743 per ton, with an annual sales volume of about 3.28 million tons.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095796/pharmaceutical-composite-films-and-bags
1. Market Size, Growth Trajectory & Core Keywords
The global market for Pharmaceutical Composite Films and Bags was estimated to be worth US$ 9,312 million in 2025 and is projected to reach US$ 12,680 million, growing at a CAGR of 4.6% from 2026 to 2032.
Core keywords: Pharmaceutical Composite Films, Multi-Layer Drug Packaging, Aluminum-Plastic Laminates, Moisture Barrier Films, IV Bags.
2. Industry Segmentation
Aluminum-Plastic Composite (50% of revenue): Aluminum foil (20–50µm) + plastic layers. Complete barrier (0% MVTR, 0% OTR). Used for moisture-sensitive drug blister packs (antibiotics, probiotics). Price: US$3,000–8,000/ton.
Plastic Composite (35%, 5.8% CAGR): Multi-layer plastic (PE/EVOH/PE, PP/EVOH/PP). High barrier (MVTR 0.5–5 g/m²/day), transparent, recyclable. Used for IV bags, enteral feeding bags. Price: US$2,500–5,000/ton.
Others (15%): Paper-aluminum-plastic, coated films.
Segment by Application
Oral: 45% (blister packs)
Injection: 30% (IV bags, sterile pouches)
Topical: 15%
Others: 10%
3. Recent Industry Data & Policy Drivers (2025)
Revenue increased 5.3% YoY, driven by moisture-sensitive drug expansion, IV bag demand, and sustainability innovations.
Plastic composites fastest-growing (5.8% CAGR) due to recyclability demands (EU PPWR 2026).
Policy impact: USP <671> (2025) requires MVTR testing, favoring aluminum-plastic (0% MVTR). EU PPWR (2026) mandates recyclability, driving shift to mono-material plastic composites. FDA requires E&L testing for plastic IV bags.
4. Technical Challenges & Solutions
Barrier vs. recyclability trade-off: Aluminum-plastic is non-recyclable. Amcor and Constantia offer recyclable high-barrier PE films (MVTR 0.5–1.5 g/m²/day) at 10–20% premium.
Formability for blister packaging: Cold-form foil must be formable without cracking. Constantia offers "low-seal-force" films reducing sealing temperature by 20–30°C (10–15% premium).
Extractables from IV bags: PVC bags leach DEHP plasticizers. West Pharmaceutical offers non-PVC bags (PE/EVOH/PE) with low extractables at 20–30% premium.
Exclusive insight: A 2025 sustainability study found aluminum-plastic composites are least recyclable (landfilled/incinerated). Mono-material pharmaceutical blister packaging (all-PP or all-PE with EVOH) is growing at 25% CAGR, priced at 15–25% premium.
5. User Case Examples
Case 1 – Oral (probiotic blister): Constantia alu-alu cold-form foil maintained <2% moisture at 24 months (vs. 8% in PVC). Shelf life extended from 12 to 36 months.
Case 2 – Injection (IV bag): West Pharmaceutical non-PVC multi-layer bag (PE/EVOH/PE) achieved OTR <5 cc/m²/day, DEHP-free, breakage 0.2% (vs. 1.5% for PVC).
6. Competitive Landscape
European/Japanese leaders: Constantia Flexibles, Amcor, TOPPAN, ZACROS (aluminum-plastic, 30–40% margin). West Pharmaceutical (non-PVC IV bags, 35–45% margin).
Chinese manufacturers (domestic focus): Jiangsu Zhongjin Matai, Shanghai Kindly, Shandong Huazhilin, Sichuan Hui Li, Harbin Pengcheng, Shandong Ujoin, Sunkey, Hubei Hongyu, Baoli, Hengshui Jiecai – >75% China domestic market at 40–60% price advantage (US$1,500–2,200/ton vs. US$3,000–6,000/ton) but lack USP <671>/FDA DMF for export.
独家观察: European/Japanese manufacturers dominate premium aluminum-plastic composites (40–50% share). Chinese manufacturers capture domestic market through NMPA VBP but lack Western regulatory clearance. EU PPWR 2026 is accelerating mono-material recyclable film development (25% CAGR). Capacity consolidation occurring among European film manufacturers (high energy costs).
7. Forecast Outlook (2026–2032)
By 2028, over 50% of pharmaceutical composite films in Europe will be mono-material (recyclable) due to PPWR mandates, and non-PVC IV bags will continue displacing PVC (>60% of Western markets). Pharmaceutical manufacturers should prioritize suppliers offering (1) certified moisture barrier (MVTR <1 g/m²/day), (2) recyclable mono-material designs, (3) E&L profiles for IV bags, (4) USP <671> certification, (5) FDA DMF/CE/NMPA clearances, and (6) sustainability certifications. The shift toward high-barrier flexible packaging for biologics and gene therapies will drive demand for advanced composite films with enhanced oxygen/moisture barriers combined with recyclability.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
Pharmaceutical manufacturers face a critical challenge: protecting moisture-sensitive and oxygen-sensitive drugs (oral solids, injectables, biologics) from environmental degradation. Single-layer plastic films allow moisture and oxygen transmission, leading to drug instability and reduced shelf life. Pharmaceutical Composite Films and Bags solve this by providing high-performance packaging made by laminating multiple layers with different properties, offering excellent barrier performance, moisture resistance, puncture resistance, and chemical stability, effectively protecting medicines from light, oxygen, and moisture to ensure efficacy and safety. From aluminum-plastic blister films for tablets to multi-layer IV bags for parenteral nutrition, composite films are essential for pharmaceutical packaging. In 2024, the average global price of pharmaceutical composite films and bags is approximately USD 2,743 per ton, with an annual sales volume of about 3.28 million tons.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095796/pharmaceutical-composite-films-and-bags
1. Market Size, Growth Trajectory & Core Keywords
The global market for Pharmaceutical Composite Films and Bags was estimated to be worth US$ 9,312 million in 2025 and is projected to reach US$ 12,680 million, growing at a CAGR of 4.6% from 2026 to 2032.
Core keywords: Pharmaceutical Composite Films, Multi-Layer Drug Packaging, Aluminum-Plastic Laminates, Moisture Barrier Films, IV Bags.
2. Industry Segmentation
Aluminum-Plastic Composite (50% of revenue): Aluminum foil (20–50µm) + plastic layers. Complete barrier (0% MVTR, 0% OTR). Used for moisture-sensitive drug blister packs (antibiotics, probiotics). Price: US$3,000–8,000/ton.
Plastic Composite (35%, 5.8% CAGR): Multi-layer plastic (PE/EVOH/PE, PP/EVOH/PP). High barrier (MVTR 0.5–5 g/m²/day), transparent, recyclable. Used for IV bags, enteral feeding bags. Price: US$2,500–5,000/ton.
Others (15%): Paper-aluminum-plastic, coated films.
Segment by Application
Oral: 45% (blister packs)
Injection: 30% (IV bags, sterile pouches)
Topical: 15%
Others: 10%
3. Recent Industry Data & Policy Drivers (2025)
Revenue increased 5.3% YoY, driven by moisture-sensitive drug expansion, IV bag demand, and sustainability innovations.
Plastic composites fastest-growing (5.8% CAGR) due to recyclability demands (EU PPWR 2026).
Policy impact: USP <671> (2025) requires MVTR testing, favoring aluminum-plastic (0% MVTR). EU PPWR (2026) mandates recyclability, driving shift to mono-material plastic composites. FDA requires E&L testing for plastic IV bags.
4. Technical Challenges & Solutions
Barrier vs. recyclability trade-off: Aluminum-plastic is non-recyclable. Amcor and Constantia offer recyclable high-barrier PE films (MVTR 0.5–1.5 g/m²/day) at 10–20% premium.
Formability for blister packaging: Cold-form foil must be formable without cracking. Constantia offers "low-seal-force" films reducing sealing temperature by 20–30°C (10–15% premium).
Extractables from IV bags: PVC bags leach DEHP plasticizers. West Pharmaceutical offers non-PVC bags (PE/EVOH/PE) with low extractables at 20–30% premium.
Exclusive insight: A 2025 sustainability study found aluminum-plastic composites are least recyclable (landfilled/incinerated). Mono-material pharmaceutical blister packaging (all-PP or all-PE with EVOH) is growing at 25% CAGR, priced at 15–25% premium.
5. User Case Examples
Case 1 – Oral (probiotic blister): Constantia alu-alu cold-form foil maintained <2% moisture at 24 months (vs. 8% in PVC). Shelf life extended from 12 to 36 months.
Case 2 – Injection (IV bag): West Pharmaceutical non-PVC multi-layer bag (PE/EVOH/PE) achieved OTR <5 cc/m²/day, DEHP-free, breakage 0.2% (vs. 1.5% for PVC).
6. Competitive Landscape
European/Japanese leaders: Constantia Flexibles, Amcor, TOPPAN, ZACROS (aluminum-plastic, 30–40% margin). West Pharmaceutical (non-PVC IV bags, 35–45% margin).
Chinese manufacturers (domestic focus): Jiangsu Zhongjin Matai, Shanghai Kindly, Shandong Huazhilin, Sichuan Hui Li, Harbin Pengcheng, Shandong Ujoin, Sunkey, Hubei Hongyu, Baoli, Hengshui Jiecai – >75% China domestic market at 40–60% price advantage (US$1,500–2,200/ton vs. US$3,000–6,000/ton) but lack USP <671>/FDA DMF for export.
独家观察: European/Japanese manufacturers dominate premium aluminum-plastic composites (40–50% share). Chinese manufacturers capture domestic market through NMPA VBP but lack Western regulatory clearance. EU PPWR 2026 is accelerating mono-material recyclable film development (25% CAGR). Capacity consolidation occurring among European film manufacturers (high energy costs).
7. Forecast Outlook (2026–2032)
By 2028, over 50% of pharmaceutical composite films in Europe will be mono-material (recyclable) due to PPWR mandates, and non-PVC IV bags will continue displacing PVC (>60% of Western markets). Pharmaceutical manufacturers should prioritize suppliers offering (1) certified moisture barrier (MVTR <1 g/m²/day), (2) recyclable mono-material designs, (3) E&L profiles for IV bags, (4) USP <671> certification, (5) FDA DMF/CE/NMPA clearances, and (6) sustainability certifications. The shift toward high-barrier flexible packaging for biologics and gene therapies will drive demand for advanced composite films with enhanced oxygen/moisture barriers combined with recyclability.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ